441785-25-7

Basic information

• Product Name: PHOSPHONIC ACID, [[[1-[(2-AMINO-9H-PURIN-9-YL)METHYL]CYCLOPROPYL]OXY]METHYL]- (9CI)
• Synonyms: PHOSPHONIC ACID, [[[1-[(2-AMINO-9H-PURIN-9-YL)METHYL]CYCLOPROPYL]OXY]METHYL]- (9CI);PHOSPHONIC ACID, [[[1-[(2-AMINO-9H-PURIN-9-YL)METHYL]CYCLOPROPYL]OXY]METHYL]-;(1-((2-Amino-9H-purin-9-yl)methyl)cyclopropoxy)methylphosphonic acid;P-[[[1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl]oxy]methyl]-Phosphonic acid;[[[1-[(2-Amino-9H-purin-9-yl)methyl]cyclopropyl]oxy]methyl]phosphonic acid;Besifovir;[1-[(2-aminopurin-9-yl)methyl]cyclopropyl]oxymethylphosphonic acid
• CAS NO: 441785-25-7
• Molecular Formula: C₁₀H₁₄N₅O₄P
• Molecular Weight: 299.223021
• Mol File: 441785-25-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 668.4°C at 760 mmHg
• Flash Point: 358°C
• Appearance: /
• Density: 1.94g/cm³
• Vapor Pressure: 8.89E-19mmHg at 25°C
• Refractive Index: 1.825
• PKA: 2.44±0.10(Predicted)
• CAS DataBase Reference: PHOSPHONIC ACID, [[[1-[(2-AMINO-9H-PURIN-9-YL)METHYL]CYCLOPROPYL]OXY]METHYL]- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: PHOSPHONIC ACID, [[[1-[(2-AMINO-9H-PURIN-9-YL)METHYL]CYCLOPROPYL]OXY]METHYL]- (9CI)(441785-25-7)
• EPA Substance Registry System: PHOSPHONIC ACID, [[[1-[(2-AMINO-9H-PURIN-9-YL)METHYL]CYCLOPROPYL]OXY]METHYL]- (9CI)(441785-25-7)

Safety Data

• Hazardous Substances Data: 441785-25-7(Hazardous Substances Data)

Usage

General Description

PHOSPHONIC ACID, [[[1-[(2-AMINO-9H-PURIN-9-YL)METHYL]CYCLOPROPYL]OXY]METHYL]- (9CI) is a chemical compound with a complex structure. It is a derivative of phosphonic acid that contains a cyclopropylmethyl group linked to an amino-purinylmethyl group. This molecule is likely to have significant biological activity due to the presence of the purine moiety, which is a key component of DNA and RNA. The phosphonic acid group also suggests potential interactions with enzymes and biological pathways. Further research is needed to fully understand the properties and potential uses of this compound.

InChI:InChI=1/C10H14N5O4P/c11-9-12-3-7-8(14-9)15(5-13-7)4-10(1-2-10)19-6-20(16,17)18/h3,5H,1-2,4,6H2,(H2,11,12,14)(H2,16,17,18)

Upstream product

• 693788-86-2 diisopropyl ({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonate 
• 441784-84-5 diisopropyl {[1-({[tert-butyl(diphenyl)silyl]oxy}methyl)cyclopropyl]oxy}methylphosphonate 
• 441784-88-9 diisopropyl ({1-[(2-amino-6-chloro-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonate 
• 441784-86-7 {1-[(diisopropylphosphoryl)methoxy]cyclopropyl}methyl methanesulfonate 
• 441784-85-6 diisopropyl {[1-(hydroxymethyl)cyclopropyl]oxy}methylphosphonate 

Downstream Products

• 441785-26-8 LB-80380 

Relevant articles and documents

Method for preparing Besifovir

The invention relates to a method for preparing P-[[[1-[(2-amino-9H-purine-9-yl) methyl] cyclopropyl] oxy] methyl]-phosphoric acid (Besifovir). The method comprises the following steps: 1) enabling acompound of formula (1) as shown in the specification to react with tertiary butyl diphenylchlorosilane so as to prepare a compound of formula (2) as shown in the specification; 2) enabling the compound of formula (2) to react with ethyl magnesium bromide so as to prepare a compound of formula (3) as shown in the specification; 3) enabling the compound of the formula (3) to react with p-toluenesulfonyl oxymethyldiethoxyphosphine under a condition that tertiary butanol lithium is adopted as an alkali so as to prepare a compound of formula (23) as shown in the specification; 4) carrying out ammonium fluoride hydrolysis on the compound of formula (23) so as to prepare a compound of formula (24) as shown in the specification; 5) enabling the compound of formula (24) to react with a compound offormula (28) as shown in the specification so as to prepare a compound as a solid of formula (22) as shown in the specification; 6) carrying out reduction dechloridation on the compound of formula (22) as shown in the specification under a condition of a catalyst and a hydrogen supplier so as to prepare a compound as a solid of formula (25) as shown in the specification; 7) carrying out trimethylbromide silane hydrolysis on the compound of formula (25), so as to obtain Besifovir as shown in the specification. The method is cheap in raw material and intermediate material, easy in raw materialand intermediate material obtaining, low in cost, high in yield, gentle in condition and good in security.

NUCLEOSIDE PHOSPHONATE DERIVATIVES USEFUL IN THE TREATMENT OF HIV INFECTIONS

The present invention relates to a method of treating HIV infections by administering a nucleoside phosphonate derivative represented by formula (I).